Data are from the National Health Institute Research Database (NHIRD), which are available to researchers in Taiwan and has been extensively used in epidemiologic studies. It is allowed to use for academic purpose only after proof by National Health Research Institute. Thus, the data cannot be made publicly available. Data requests may be sent to National Health Institute Research Database (<http://nhird.nhri.org.tw/>) at <nhird@nhri.org.tw>.

Introduction {#sec001}
============

Sudden sensorineural hearing loss (SSNHL) is often an unexpected and traumatic experience for patients. SSNHL is defined as a sudden loss of more than 30 dB of hearing acuity in three contiguous frequencies within 72 h \[[@pone.0175266.ref001]\]. SSNHL is usually classified as idiopathic because the causative factor is not identified in most cases \[[@pone.0175266.ref002]\]. The potential causes of SSNHL include vascular disorders, viral infection, autoimmune disorders, neurological disorders, neoplasms, and ototoxic drugs \[[@pone.0175266.ref003]\].

Several studies have discussed the presence of viral infection in patients with SSNHL \[[@pone.0175266.ref004]--[@pone.0175266.ref006]\], and the types of viruses implicated in such cases include mumps, cytomegalovirus, measles, rubella, varicella zoster virus, herpes simplex virus, enteroviruses, and human immunodeficiency virus \[[@pone.0175266.ref005]--[@pone.0175266.ref007]\]. Hepatitis virus infection has been correlated with SSNHL in only a small number of case reports \[[@pone.0175266.ref008]--[@pone.0175266.ref011]\]. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections have emerged as a global health problem, and as many as 350 million and 123 million individuals have been infected with HBV and HCV, respectively, worldwide \[[@pone.0175266.ref012], [@pone.0175266.ref013]\]. In highly endemic areas such as Taiwan, the prevalence of chronic HBV infection is estimated to be between 15% and 20% \[[@pone.0175266.ref014], [@pone.0175266.ref015]\], whereas the prevalence of HCV is estimated at 4%--10% in the general population \[[@pone.0175266.ref016], [@pone.0175266.ref017]\]. Chronic HBV or HCV infections have been proven to increase the risk of hepatocellular carcinoma \[[@pone.0175266.ref018]\]. We are interested in investigating whether HBV or HCV infections have an impact on the incidence of SSNHL.

To assess the association between HBV or HCV infection and the subsequent development of SSNHL, we conducted a nationwide population-based cohort study by analyzing data from a nationwide medical database, the National Health Insurance Research Database.

Materials and methods {#sec002}
=====================

Data sources {#sec003}
------------

In this study, we used data from the National Health Insurance Research Database (NHIRD) to investigate the association between hepatitis virus infections, including HBV and HCV infection, and SSNHL over a 10-year period (2000--2010), from the outpatient and hospitalization Longitudinal Health Insurance Database in Taiwan.

Study design and sampled participants {#sec004}
-------------------------------------

### Study design {#sec005}

This study was a retrospective matched-cohort design.

### Sample {#sec006}

Patients with HBV or HCV infections were selected from 1 January 2000 to 31 December 2010, according to the International Classification of Diseases, Version 9, Clinical Modification (ICD-9-CM) codes 070.20, 070.22, 070.30, 070.32, and V02.61 for HBV and 070.41, 070.44, 070.51, 070.54, 070.70, 070.71, and V02.62 for HCV. Patients diagnosed with SSNHL (ICD-9-CM code: 388.2) before 2000 or before the first visit for viral hepatitis were excluded. In addition, all patients aged \<20 years were also excluded. A total of 683,768 participants were enrolled in this study; among these, 170,942 had HBV or HCV infection and 512,826 were controls without HBV or HCV infection who were matched by age, sex, and index year ([Fig 1](#pone.0175266.g001){ref-type="fig"}).

![Flowchart of study sample selection from the National Health Insurance Research Database in Taiwan.](pone.0175266.g001){#pone.0175266.g001}

Covariates {#sec007}
----------

The covariates included sex and age group (20--29, 30--39, 40--49, 50--59, 60--69, ≥70 years).

Comorbidity {#sec008}
-----------

Baseline comorbidities included diabetes mellitus (DM; ICD-9-CM code: 250); hypertension (ICD-9-CM codes: 401--405); depression (ICD-9-CM codes: 296.2, 296.3, 296.82, 300.4, and 311); stroke (ICD-9-CM codes: 430--438); chronic kidney disease (CKD; ICD-9-CM code: 585); osteoporosis (ICD-9-CM codes: 733.00--733.09); nephritis, nephrotic syndrome, and nephrosis (ICD-9-CM codes: 580--589); hyperlipidemia (ICD-9-CM code: 272); and systemic lupus erythematosus (SLE; ICD-9-CM code: 710.0).

Data analysis {#sec009}
-------------

All statistical analyses were performed using IBM SPSS for Windows, Version 22.0 (IBM Corp., Armonk, NY, USA). χ^2^ and t tests were used to evaluate the distributions of categorical and continuous variables, respectively. Multivariate Cox proportional hazards regression analysis was used to determine the risk of SSNHL, and the results are presented as hazard ratio (HR) with 95% confidence interval (CI). The difference in the risk of SSNHL between the study (with HBV/HCV) and control (without HBV/HCV) groups was estimated using the Kaplan--Meier method with the log-rank test. A two-tailed P value of \<0.05 was considered to indicate statistical significance.

Ethics statement {#sec010}
----------------

This study was conducted in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki). The NHIRD encrypts personal patient information to maintain privacy and provides researchers with anonymous identification numbers associated with relevant claim information. Patient consent is not required for accessing the NHIRD. The Institutional Review Board of Tri-Service General Hospital approved this study (TSGHIRB No. 2-104-05-126). The committee waived the need for written informed consent.

Results {#sec011}
=======

Characteristics of the prevalence of SSNHL, covariates, and comorbidities at the end of follow-up for patients with HBV/HCV infection compared with those without HBV/HCV infection {#sec012}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

According to the assessed data from January 1, 2000, to December 31, 2010, 170,942 patients with HBV/HCV infection fulfilled the eligibility criteria and 512,826 matched individuals were selected as controls ([Fig 1](#pone.0175266.g001){ref-type="fig"}). In our matched-cohort study, no significant differences were observed between the HBV/HCV and control groups in sex and age distribution at baseline. At the end of follow-up ([Table 1](#pone.0175266.t001){ref-type="table"}), 647 (0.38%, 647/170,942) patients developed SSNHL in the HBV/HCV group compared with 978 (0.19%, 978/512,826) in the control group; this difference was statistically significant (P \< 0.001). Additionally, in the HVB/HCV group, a higher rate of the participants was observed among those in the 20--59-year age group (58.39% vs. 51.37%) and those with some comorbidities (depression, 1.09% vs. 0.81%; SLE, 0.18% vs. 0.13%) compared with the control group.

10.1371/journal.pone.0175266.t001

###### Characteristics of the study participants at the end of follow-up.

![](pone.0175266.t001){#pone.0175266.t001g}

  HBV / HCV                                          Total     With    Without   P                         
  -------------------------------------------------- --------- ------- --------- ------- --------- ------- ---------
  **Total**                                          683,768           170,942   25.00   512,826   75.00   
  **SSNHL**                                                                                                \<0.001
    Without                                          689,143   99.76   170,295   99.62   518,848   99.81   
    With                                             1,625     0.24    647       0.38    978       0.19    
  **Gender**                                                                                               0.999
    Male                                             440,600   64.44   110,150   64.44   330,450   64.44   
    Female                                           243,168   35.56   60,792    35.56   182,376   35.56   
  **Age group (years)**                                                                                    0.036
    20--29                                           37,142    5.42    10,218    6.96    25,124    4.90    
    30--39                                           76,708    11.19   20,367    11.79   56,341    10.99   
    40--49                                           112,488   16.41   30,710    17.78   81,778    15.95   
    50--59                                           137,940   20.12   37,765    21.86   100,175   19.53   
    60--69                                           132,244   19.29   33,033    19.12   99,211    19.35   
    ≧70                                              189,046   27.58   38,849    22.49   150,197   29.29   
  **Diabetes mellitus (DM)**                                                                               \<0.001
    Without                                          579,370   84.73   145,758   85.27   433,612   84.55   
    With                                             104,398   15.27   25,184    14.73   79,214    15.45   
  **Hypertension**                                                                                         \<0.001
    Without                                          568,594   83.16   144,676   84.63   423,918   82.66   
    With                                             115,174   16.84   26,266    15.37   88,908    17.34   
  **Depression**                                                                                           \<0.001
    Without                                          677,732   99.12   169,073   98.91   508,659   99.19   
    With                                             6,036     0.88    1,869     1.09    4,167     0.81    
  **Stroke**                                                                                               \<0.001
    Without                                          635,547   93.00   164,379   96.36   471,168   91.88   
    With                                             47,861    7.00    6,203     3.64    41,658    8.12    
  **Chronic Kidney Disease (CKD)**                                                                         \<0.001
    Without                                          663,782   97.08   166,862   97.61   496,920   96.90   
    With                                             19,986    2.92    4,080     2.39    15,906    3.10    
  **Osteoporosis**                                                                                         \<0.001
    Without                                          683,543   99.57   170,492   99.74   513,051   99.52   
    With                                             2,925     0.43    450       0.26    2,475     0.48    
  **Nephritis, nephrotic syndrome, and nephrosis**                                                         \<0.001
    Without                                          638,130   93.33   160,600   93.95   477,530   93.12   
    With                                             45,638    6.67    10,342    6.05    35,296    6.88    
  **Hyperlipidaemia**                                                                                      \<0.001
    Without                                          666,821   97.52   167,716   98.11   499,105   97.32   
    With                                             16,947    2.48    3,226     1.89    13,721    2.68    
  **Systemic lupus erythematosus (SLE)**                                                                   \<0.001
    Without                                          682,811   99.86   170,632   99.82   512,179   99.87   
    With                                             957       0.14    310       0.18    647       0.13    

P-value (categorical variable: chi-square/Fisher exact test). DM: ICD-9-CM code, 250; Hypertension: ICD-9-CM codes, 401--405; Depression: ICD-9-CM codes, 296.2--296.3, 296.82, 300.4, and 311; Stroke: ICD-9-CM codes, 430--438; CKD: ICD-9-CM code, 585;Osteoporosis: ICD-9-CM code, 733.0x; Nephritis, nephrotic syndrome, and nephrosis: ICD-9-CM codes, 580--589; Hyperlipidemia: ICD-9-CM code, 272; SLE: ICD-9-CM code, 710.0. HBV, hepatitis B virus; HCV, hepatitis C virus.

Kaplan--Meier model for cumulative risk of SSNHL in HBV/HCV infection {#sec013}
---------------------------------------------------------------------

The cumulative incidence curve for SSNHL in the total HBV/HCV infection cohort was significantly higher than that for the comparison cohort, after adjustment for age, sex, and comorbidities ([Fig 2](#pone.0175266.g002){ref-type="fig"}, log-rank test; P \< 0.001). In the patients with HBV/HCV infections, the risk of SSNHL increased progressively with the duration of follow-up, rather than with being limited to the immediate days after a diagnosis of HBV/HCV infection. In the subgroups of HBV and HCV infection, the same trend was independently revealed ([Fig 2](#pone.0175266.g002){ref-type="fig"}).

![Kaplan--Meier curves for the cumulative risk of SSNHL among patients aged ≥20 years with HBV/HCV infection (stratified by HBV or HCV alone, using the log-rank test).](pone.0175266.g002){#pone.0175266.g002}

HRs and incidence of SSNHL stratified by sex, age group, and comorbidities, by using Cox regression for patients with HBV/HCV infection compared with those without HBV/HCV infection {#sec014}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cox proportional hazards regressions analysis revealed an increased risk of SSNHL, with an adjusted HR of 5.103 (95% CI, 4.585--5.678), in patients with HBV/HCV infection, after adjustment for sex, age, and comorbidities ([Table 2](#pone.0175266.t002){ref-type="table"}). Adjusted HRs of 4.825 (95% CI, 4.216--5.521) and 5.582 (95% CI, 4.686--6.651) for developing SSNHL were observed in male and female patients with HBV/HCV infection, respectively, compared with the control group (P \< 0.001). Among all age groups, a higher adjusted HR for SSNHL was observed in the HBV/HCV group than in the control group. Regardless of the presence of the comorbidities of DM; hypertension; depression; stroke; CKD; osteoporosis; nephritis, nephrotic syndrome, and nephrosis; and hyperlipidemia, a higher adjusted HR (ranging from 2.356 to 15.114) was observed in patients with HBV/HCV infection than in the controls (P \< 0.001).

10.1371/journal.pone.0175266.t002

###### Factors for sudden sensorineural hearing loss at the end of follow-up, stratified by variables assessed through Cox regression analysis.

![](pone.0175266.t002){#pone.0175266.t002g}

  HBV / HCV                                          With   Without      Ratio    Adjusted HR   95%CI          95%CI   P                                  
  -------------------------------------------------- ------ ------------ -------- ------------- -------------- ------- -------- -------- ------- -------- ---------
  **Total**                                          647    228,486.24   283.17   978           1,983,509.96   49.31   5.743    5.103    4.585   5.678    \<0.001
  **Gender**                                                                                                                                              
    Male                                             395    144,922.93   272.56   640           1,265,581.36   50.57   5.390    4.825    4.216   5.521    \<0.001
    Female                                           252    83,563.30    301.57   338           717,928.60     47.08   6.405    5.582    4.686   6.651    \<0.001
  **Age group (years)**                                                                                                                                   
    20--29                                           33     6,456.16     511.14   14            28,548.24      49.04   10.423   8.967    4.716   17.050   \<0.001
    30--39                                           71     20,412.07    347.83   53            127,576.93     41.54   8.373    7.940    5.448   11.572   \<0.001
    40--49                                           111    34,115.41    325.37   160           223,115.13     71.71   4.537    4.581    3.537   5.933    \<0.001
    50--59                                           176    49,194.50    357.76   294           371,528.37     79.13   4.521    4.328    3.542   5.288    \<0.001
    60--69                                           125    50,012.10    249.94   256           463,103.63     55.28   4.521    4.061    3.225   5.114    \<0.001
    ≧70                                              131    68,296.00    191.81   201           769,637.65     26.12   7.345    6.426    5.070   8.145    \<0.001
  **Diabetes mellitus (DM)**                                                                                                                              
    Without                                          529    183,848.75   287.74   740           1,556,145.80   47.55   6.051    5.421    4.809   6.111    \<0.001
    With                                             118    44,637.48    264.35   238           427,364.15     55.69   4.747    3.958    3.117   5.026    \<0.001
  **Hypertension**                                                                                                                                        
    Without                                          533    187,115.65   284.85   745           1,466,869.58   50.79   5.609    5.016    4.456   5.646    \<0.001
    With                                             114    41,371.18    275.55   233           516,640.38     45.10   6.110    5.446    4.253   6.976    \<0.001
  **Depression**                                                                                                                                          
    Without                                          639    225,164.07   283.79   974           1,960,769.42   49.67   5.713    5.065    4.550   5.638    \<0.001
    With                                             8      3,322.17     240.81   4             22,740.53      17.59   13.690   15.114   4.027   56.720   \<0.001
  **Stroke**                                                                                                                                              
    Without                                          628    217,345.56   288.94   935           1,793,066.24   52.15   5.541    5.019    4.503   5.594    \<0.001
    With                                             19     11,140.67    170.55   43            190,443.72     22.58   7.553    7.721    4.317   13.608   \<0.001
  **Chronic Kidney Disease (CKD)**                                                                                                                        
    Without                                          634    220,596.40   287.40   945           1,917,281.65   49.29   5.831    5.208    4.673   5.804    \<0.001
    With                                             13     7,889.64     164.77   33            66,228.30      49.83   3.307    2.356    1.188   4.672    0.014
  **Osteoporosis**                                                                                                                                        
    Without                                          645    227,630.31   283.35   974           1,970,764.78   49.42   5.733    5.094    4.578   5.669    \<0.001
    With                                             2      855.92       233.67   4             12,745.17      31.38   7.445    8.052    1.333   48.659   0.023
  **Nephritis, nephrotic syndrome, and nephrosis**                                                                                                        
    Without                                          609    210,808.81   288.89   929           1,839,943.17   50.49   5.722    5.144    4.608   5.742    \<0.001
    With                                             38     17,677.42    214.96   49            143,566.78     34.13   6.298    4.540    2.873   7.174    \<0.001
  **Hyperlipidaemia**                                                                                                                                     
    Without                                          609    224,485.09   271.29   929           1,905,167.63   48.76   5.563    4.944    4.436   5.510    \<0.001
    With                                             38     4,001.15     949.73   49            78,342.32      62.55   15.184   12.440   6.860   22.558   \<0.001
  **Systemic lupus erythematosus (SLE)**                                                                                                                  
    Without                                          644    227,931.26   282.54   975           1,980,062.17   49.24   5.738    5.109    4.591   5.686    \<0.001
    With                                             3      554.97       540.57   3             3,447.79       87.01   6.213    4.032    0.701   23.198   0.118

PYs, person-years; adjusted HR, adjusted hazard ratio: adjusted for the variables listed in the Cox regression table; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.

Comparison of HRs among the HBV/HCV, HBV, and HCV groups for the risk of SSNHL {#sec015}
------------------------------------------------------------------------------

Cox proportional hazards regressions analysis revealed an increased risk of SSNHL, with an incidence rate ratio (IRR) of 5.743 (95% CI, 4.585--5.678) in the HBV/HCV group, after adjustment for sex, age, and comorbidities. In addition, the individual IRRs for SSNHL in the subgroups of HBV (3.24) and HCV (2.503) were identified. All adjusted HRs for the risk of SSNHL were similar among the HBV/HCV (5.103; 95% CI, 4.585--5.678), HBV (5.110; 95% CI, 4.495--5.809), and HCV (5.094; 95% CI, 4.437--5.848) groups compared with the control group (P \< 0.001; [Table 3](#pone.0175266.t003){ref-type="table"}).

10.1371/journal.pone.0175266.t003

###### Factors for sudden sensorineural hearing loss in the HBV/HCV group and the HBV and HCV subgroups at the end of follow-up, assessed through Cox regression analysis.

![](pone.0175266.t003){#pone.0175266.t003g}

  HBV / HCV   With   Without      Ratio    Adjusted HR   95%CI          95%CI   P                               
  ----------- ------ ------------ -------- ------------- -------------- ------- ------- ------- ------- ------- ---------
  **Total**   647    228,486.24   283.17   978           1,983,509.96   49.31   5.743   5.103   4.585   5.678   \<0.001
  **HBV**     365    228,486.24   159.75   978           1,983,509.96   49.31   3.240   5.110   4.495   5.809   \<0.001
  **HCV**     282    228,486.24   123.42   978           1,983,509.96   49.31   2.503   5.094   4.437   5.848   \<0.001

PYs, person-years; adjusted HR, adjusted hazard ratio: adjusted for the variables listed in the Cox regression table; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus.

Discussion {#sec016}
==========

To the best of our knowledge, this is the first large-scale retrospective matched-cohort study to explore the association between SSNHL and HBV/HCV infection. The main finding of this study was that patients who were diagnosed as having HBV/HCV infections between January 1, 2000, and December 31, 2010, had a significantly higher incidence of SSNHL, with an IRR of 5.743 (P \< 0.001), than did the general population without HBV/HCV infections.

The prevalence of HBV/HCV infections varies from \<0.5% in Western countries to 8%--25% in endemic countries in East Asia \[[@pone.0175266.ref019]\]. In our study, the prevalence of HBV/HCV infections was 17.4%. Compared with females, males were predominantly infected with HBV/HCV (110,150 males vs. 60,792 females). The age at diagnosis of HBV/HCV infection was usually \>40 years, which was compatible with a previous report describing a mean age at diagnosis of 42 years; 60% of these were male patients \[[@pone.0175266.ref020]\]. In addition, our study demonstrated that the development of SSNHL was most common in patients aged ≥40 years, and that most patients with development of SSNHL were men (395 males vs. 252 females).

At the end of follow-up, all comorbidities were significantly differentially distributed between the HBV/HCV and control groups ([Table 1](#pone.0175266.t001){ref-type="table"}). In the HVB/HCV group, a lower rate of the participants with individual comorbidity was observed for most comorbidities, whereas for depression and SLE, a higher rate of the participants was observed compared with the control group. A higher frequency of some degree of depression was reported in both hepatitis B and C patients \[[@pone.0175266.ref021]\]. However, our finding of a higher percentage of SLE in patients with HBV/HCV infection was inconsistent with previous results \[[@pone.0175266.ref022]\]. Additional in-depth investigations are warranted to explore the codependence among these comorbidities and HBV/HCV infections through multivariate analyses.

Our data revealed that the incidence of SSNHL was approximately two-fold higher in the HBV/HCV group than in the control group, and that this difference was significant. The general estimated incidence of SSNHL varies from 5 to 20 cases per 100,000 per year \[[@pone.0175266.ref001]\]. In our study, the annual incidence of SSNHL was approximately 38 cases per 100,000 in the HBV/HCV group compared with 19 cases per 100,000 in the control group. The incidence noted in our study was relatively high because the use of a nationwide and large-scale survey may have increased the number of patients treated for SSNHL in outpatient and inpatient departments. In a previous report, the annual SSNHL incidence in Taiwan ranged between 6.49 and 10.21 per 100,000; this number included only the SSNHL patients with hospital admission \[[@pone.0175266.ref023]\].

Despite the association between HBV/HCV infection and several risk factors for SSNHL, the risk of SSNHL remained significantly higher in the HBV/HCV infection cohort, after adjustment for sex, age group, and comorbidities. The association between HBV/HCV infections and SSNHL may be because of shared risk factors. However, we can confidently claim that the increased risk of SSNHL in these patients was likely the effect of HBV/HCV infection, because the possible confounding factors for SSNHL were already substantially adjusted for in this study. Even in the subgroups of HBV or HCV infection alone, a significantly increased risk of SSNHL (with a higher adjusted HR) was observed compared with the control group. These data indicate that hepatitis virus infection has a very strong impact on the risk of SSNHL.

The underlying mechanisms linking HBV/HCV infections with SSNHL development remain unclear. We hypothesized that, in patients with HBV/BCV infections, SSNHL could occur due to an acute exacerbation of viral hepatitis and subsequent SNHL \[[@pone.0175266.ref008]\] or a chronic viral reaction causing chronic hearing loss \[[@pone.0175266.ref024], [@pone.0175266.ref025]\]. Viruses could gain access to the inner ear via the hematogenous route and induce severe pathophysiologic changes or an immune-mediated reaction \[[@pone.0175266.ref008]\]. HBV/HCV infections can stimulate the production of inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1, and interleukin-6, which are injurious to the cochlear hair cells \[[@pone.0175266.ref026]\]. In addition, hepatitis virus infection has a well-documented association with polyarteritis nodosa, which is a life-threatening necrotizing vasculitis that may result in hearing loss \[[@pone.0175266.ref024], [@pone.0175266.ref027]\].

Our results demonstrate that a greatly increased risk of SSNHL was observed in patients with HBV/HCV infections, according to the data of a large population (170,942 patients with HBV/HCV and 512,826 controls) selected from a retrospective matched-cohort comprising 1,000,000 people covered by the National Health Insurance program; the large sample size benefitted the statistical analysis. This large data resource enables us to investigate the risk factors for SSNHL in Taiwan, with an acceptable selection bias and an enhanced statistical precision.

Our research has several shortcomings. First, several potentially confounding risk factors, such as alcohol consumption, smoking, ototoxic drug effects, and noise exposure for SSNHL, were unavailable in the data resource, which may have led to a certain bias \[[@pone.0175266.ref028]\]. Second, the database did not provide audiometric results regarding the degree of hearing impairment or routine blood and biochemistry tests data. Third, a population-based study cannot clarify the real mechanism underlying the association between HBV/HCV infection and SSNHL because extracting cochlear tissue pathogens or detecting cochlear injury through imaging is very difficult \[[@pone.0175266.ref007], [@pone.0175266.ref008]\]. In addition, patients who developed SSNHL due an ototoxic effect after antiviral drug administration for HVB/HCV infection (which has been reported in some studies) could not be excluded \[[@pone.0175266.ref010], [@pone.0175266.ref011]\]. However, a case--control study revealed pegylated interferon plus ribavirin therapy does not have any impact on the hearing thresholds of patients with HCV \[[@pone.0175266.ref029]\]. Finally, we could not exclude the possibility of virus-unrelated hepatitis, such as alcohol-related hepatitis, being correlated with the risk of SSNHL. Additional large-scale studies need to be performed to clarify the discrepancy between virus-induced SSNHL and hepatitis-induced SSNHL. Despite these limitations, this study contributes to the awareness of the increased risk of SSNHL in HBV/HCV-infected populations.

Conclusions {#sec017}
===========

In this study, HBV/HCV infections present a clearly elevated risk for SSNHL. Regular audiometric tests are recommended for patients with HBV/HCV infection to assess their hearing ability and enable the earlier detection of SSNHL. We also suggest that HBV or HCV carriers presenting with the sudden onset of hearing loss should be examined for the possibility of acute exacerbation of chronic HBV/HCV infection.
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